Skip to main navigation Skip to search Skip to main content

Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies

  • Qatar University
  • Final International University

Research output: Contribution to journal › Review article › peer-review

20 Scopus citations

Abstract

Epidermal growth factor receptor (EGFR), which is referred to as ErbB1/HER1, is the prototype of the EGFR family of receptor tyrosine kinases which also comprises ErbB2 (Neu, HER2), ErbB3 (HER3), and ErbB4 (HER4). EGFR, along with other ErbBs, is expressed in the kidney tubules and is physiologically involved in nephrogenesis and tissue repair, mainly following acute kidney injury. However, its sustained activation is linked to several kidney pathologies, including diabetic nephropathy, hypertensive nephropathy, glomerulonephritis, chronic kidney disease, and renal fibrosis. This review aims to provide a summary of the recent findings regarding the consequences of EGFR activation in several key renal pathologies. We also discuss the potential interplay between EGFR and the reno-protective angiotensin-(1–7) (Ang-(1–7), a heptapeptide member of the renin-angiotensin-aldosterone system that counter-regulates the actions of angiotensin II. Ang-(1–7)-mediated inhibition of EGFR transactivation might represent a potential mechanism of action for its renoprotection. Our review suggests that there is a significant body of evidence supporting the potential inhibition of EGFR/ErbB, and/or administration of Ang-(1–7), as potential novel therapeutic strategies in the treatment of renal pathologies. Thus, EGFR inhibitors such as Gefitinib and Erlinotib that have an acceptable safety profile and have been clinically used in cancer chemotherapy since their FDA approval in the early 2000s, might be considered for repurposing in the treatment of renal pathologies.

Original languageEnglish
Article number1394997
JournalFrontiers in Pharmacology
Volume15
DOIs
StatePublished - 2024
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • ErbB
  • acute kidney injury (AKI)
  • chronic kidney disease
  • diabetic nephropathy
  • epidermal growth factor receptor
  • glomerulonephritis
  • hypertensive nephropathy
  • renal fibrosis

Fingerprint

Dive into the research topics of 'Targeting the epidermal growth factor receptor (EGFR/ErbB) for the potential treatment of renal pathologies'. Together they form a unique fingerprint.

Cite this